The combination of PD-1/PD-L1 inhibitors plus chemotherapy received FDA approval in 2018 for first-line treatment of NSCLC patients, following favorable results in phase III clinical trials (KEYNOTE-021 study [6], IMpower150 study [7], KEYNOTE-189 study [8], KEYNOTE-407 study [9] and IMpower131 study [10]). The gene discussed is CD274; the disease is non-small cell lung carcinoma.